Nf1 mutant mice with p19ARF gene loss develop accelerated hematopoietic disease resembling acute leukemia with a variable phenotype

Stephen M Wiesner, Jennifer L. Geurts, Miechaleen D. Diers, Rachel J Bergerson, Diane E. Hasz, Kelly J. Morgan, David A Largaespada

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Juvenile Myelomonocytic Leukemia (JMML) is a relentlessly progressive myeloproliferative/myelodysplastic (MPD/MDS) hematopoietic disorder more common in patients with any one of at least three distinct genetic lesions, specifically NF1 gene loss and PTPN11 and NRAS mutations. NF1 and PTPN11 are molecular lesions associated with Neurofibromatosis Syndrome Type I (NF1 Syndrome) and Noonan's Syndrome, respectively. The occurrence of JMML is rare; even among those predisposed with these syndromes to development of disease, and secondary genetic events likely contribute to the development and progression of disease. In NF1 syndrome, loss of p53 function is a common event in solid tumors, but uncommon in JMML, suggesting that the p53 pathway may be modified by other events in this hematopoietic disorder. The work presented here investigates the possible role of the p19Arf (p19) tumor suppressor in development of MPD associated with Nf1 gene loss in mice. We find that Nf1 mutant hematopoietic cells with loss of p19 develop accelerated hematopoietic disease similar to acute leukemia with a variable phenotype. This suggests that p19 may play a role in development of JMML and evaluation of the human p19 homolog (p14ARF) in JMML may be informative.

Original languageEnglish (US)
Pages (from-to)579-585
Number of pages7
JournalAmerican Journal of Hematology
Volume86
Issue number7
DOIs
StatePublished - Jul 1 2011

Fingerprint

Juvenile Myelomonocytic Leukemia
Acute Disease
Leukemia
Phenotype
Genes
Neurofibromatosis 1 Genes
Tumor Suppressor Protein p14ARF
Noonan Syndrome
Inborn Genetic Diseases
Neurofibromatoses
Neurofibromatosis 1
Disease Progression
Neoplasms
Mutation

Cite this

Nf1 mutant mice with p19ARF gene loss develop accelerated hematopoietic disease resembling acute leukemia with a variable phenotype. / Wiesner, Stephen M; Geurts, Jennifer L.; Diers, Miechaleen D.; Bergerson, Rachel J; Hasz, Diane E.; Morgan, Kelly J.; Largaespada, David A.

In: American Journal of Hematology, Vol. 86, No. 7, 01.07.2011, p. 579-585.

Research output: Contribution to journalArticle

@article{f23a3526dc174759b5b2b47fc8b1de8a,
title = "Nf1 mutant mice with p19ARF gene loss develop accelerated hematopoietic disease resembling acute leukemia with a variable phenotype",
abstract = "Juvenile Myelomonocytic Leukemia (JMML) is a relentlessly progressive myeloproliferative/myelodysplastic (MPD/MDS) hematopoietic disorder more common in patients with any one of at least three distinct genetic lesions, specifically NF1 gene loss and PTPN11 and NRAS mutations. NF1 and PTPN11 are molecular lesions associated with Neurofibromatosis Syndrome Type I (NF1 Syndrome) and Noonan's Syndrome, respectively. The occurrence of JMML is rare; even among those predisposed with these syndromes to development of disease, and secondary genetic events likely contribute to the development and progression of disease. In NF1 syndrome, loss of p53 function is a common event in solid tumors, but uncommon in JMML, suggesting that the p53 pathway may be modified by other events in this hematopoietic disorder. The work presented here investigates the possible role of the p19Arf (p19) tumor suppressor in development of MPD associated with Nf1 gene loss in mice. We find that Nf1 mutant hematopoietic cells with loss of p19 develop accelerated hematopoietic disease similar to acute leukemia with a variable phenotype. This suggests that p19 may play a role in development of JMML and evaluation of the human p19 homolog (p14ARF) in JMML may be informative.",
author = "Wiesner, {Stephen M} and Geurts, {Jennifer L.} and Diers, {Miechaleen D.} and Bergerson, {Rachel J} and Hasz, {Diane E.} and Morgan, {Kelly J.} and Largaespada, {David A}",
year = "2011",
month = "7",
day = "1",
doi = "10.1002/ajh.22035",
language = "English (US)",
volume = "86",
pages = "579--585",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "7",

}

TY - JOUR

T1 - Nf1 mutant mice with p19ARF gene loss develop accelerated hematopoietic disease resembling acute leukemia with a variable phenotype

AU - Wiesner, Stephen M

AU - Geurts, Jennifer L.

AU - Diers, Miechaleen D.

AU - Bergerson, Rachel J

AU - Hasz, Diane E.

AU - Morgan, Kelly J.

AU - Largaespada, David A

PY - 2011/7/1

Y1 - 2011/7/1

N2 - Juvenile Myelomonocytic Leukemia (JMML) is a relentlessly progressive myeloproliferative/myelodysplastic (MPD/MDS) hematopoietic disorder more common in patients with any one of at least three distinct genetic lesions, specifically NF1 gene loss and PTPN11 and NRAS mutations. NF1 and PTPN11 are molecular lesions associated with Neurofibromatosis Syndrome Type I (NF1 Syndrome) and Noonan's Syndrome, respectively. The occurrence of JMML is rare; even among those predisposed with these syndromes to development of disease, and secondary genetic events likely contribute to the development and progression of disease. In NF1 syndrome, loss of p53 function is a common event in solid tumors, but uncommon in JMML, suggesting that the p53 pathway may be modified by other events in this hematopoietic disorder. The work presented here investigates the possible role of the p19Arf (p19) tumor suppressor in development of MPD associated with Nf1 gene loss in mice. We find that Nf1 mutant hematopoietic cells with loss of p19 develop accelerated hematopoietic disease similar to acute leukemia with a variable phenotype. This suggests that p19 may play a role in development of JMML and evaluation of the human p19 homolog (p14ARF) in JMML may be informative.

AB - Juvenile Myelomonocytic Leukemia (JMML) is a relentlessly progressive myeloproliferative/myelodysplastic (MPD/MDS) hematopoietic disorder more common in patients with any one of at least three distinct genetic lesions, specifically NF1 gene loss and PTPN11 and NRAS mutations. NF1 and PTPN11 are molecular lesions associated with Neurofibromatosis Syndrome Type I (NF1 Syndrome) and Noonan's Syndrome, respectively. The occurrence of JMML is rare; even among those predisposed with these syndromes to development of disease, and secondary genetic events likely contribute to the development and progression of disease. In NF1 syndrome, loss of p53 function is a common event in solid tumors, but uncommon in JMML, suggesting that the p53 pathway may be modified by other events in this hematopoietic disorder. The work presented here investigates the possible role of the p19Arf (p19) tumor suppressor in development of MPD associated with Nf1 gene loss in mice. We find that Nf1 mutant hematopoietic cells with loss of p19 develop accelerated hematopoietic disease similar to acute leukemia with a variable phenotype. This suggests that p19 may play a role in development of JMML and evaluation of the human p19 homolog (p14ARF) in JMML may be informative.

UR - http://www.scopus.com/inward/record.url?scp=79959347114&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959347114&partnerID=8YFLogxK

U2 - 10.1002/ajh.22035

DO - 10.1002/ajh.22035

M3 - Article

C2 - 21681782

AN - SCOPUS:79959347114

VL - 86

SP - 579

EP - 585

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 7

ER -